GSKGlaxoSmithKlineNot started yet
Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 150 (planned)
- Started
- Aug 3, 2026
- Main results expected
- Feb 28, 2029
- Fully finished
- Feb 11, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of participants with grade greater than or equal to (>=)3 corneal events assessed by keratopathy visual acuity (KVA) scale
Measured over: Up to approximately 4.5 years
Percentage of participants with grade >=3 corneal events assessed by KVA scale up to Month 6
Measured over: Up to Month 6
Percentage of Participants With Grade >=3 Corneal Events Assessed by KVA scale from 6 to 12 months
Measured over: From 6 to 12 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07614360 · record last updated 2026-06-24 · checked 2026-11-09 15:47 UTC